Trimetazidine: transparency. Information withheld from patients.
The need to reassess trimetazidine therapy after the first 3 months is mentioned in the summary of product characteristics but not in the patient information leaflet. But patients are the first to be affected!
D022126:Access to Information; D003257:Consumer Product Safety; D004348:Drug Labeling; D005602:France; D006801:Humans; D014292:Trimetazidine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D014292:Trimetazidine